Financial Data and Key Metrics Changes - Global net revenue for Q3 2025 was $69 million, representing a 13% increase compared to Q3 2024 [30] - Gross margin for Q3 was reported at 66.5%, with adjusted gross margin at 67.6% [31] - Non-GAAP operating loss for Q3 was $3.1 million, an improvement from a loss of $6.7 million in Q3 2024 [35] Business Line Data and Key Metrics Changes - Jeuveau revenue for Q3 was $63.2 million, while Evolisse contributed $5.7 million [31] - The Evolus consumer loyalty program grew to over 1.3 million members, a 34% increase year-on-year [7] - Evolisse's revenue increased sequentially to approximately $5 million after initial stocking [14] Market Data and Key Metrics Changes - The U.S. aesthetic market remains down in single digits, but Jeuveau outperformed the category with unit volume growth year-to-date [10][12] - The company strengthened its market share to 14% in the U.S. year-to-date [13] Company Strategy and Development Direction - Evolus aims to achieve profitability in 2025 and sustainable annual profitability starting in 2026 [11][37] - The company is focusing on expanding its portfolio and has introduced a bundled offering to drive market share gains [15][56] - Evolus is actively pursuing strategic business development opportunities to expand its pipeline [29] Management's Comments on Operating Environment and Future Outlook - Management noted early signs of stabilization in consumer demand for injectables, despite challenges in the aesthetic market [11] - The company remains confident in navigating potential tariff impacts and maintaining financial performance [18][32] Other Important Information - Evolus submitted a PMA to the U.S. FDA for Evolve's Sculpt, with potential approval anticipated in 2026 [17] - The company has taken proactive measures to mitigate potential tariff impacts on pharmaceuticals, including Jeuveau [18][32] Q&A Session Summary Question: Can you discuss the dynamics of Evolisse and the impact of market sentiment? - Management highlighted that initial training is crucial for product adoption, with significant inflection points observed after second training sessions [44][45] - The market is currently facing challenges, but Q4 is expected to be stronger due to accumulated experience and seasonal factors [48] Question: What are the usage trends between Evolisse Smooth and Form? - Both products are used for the nasolabial fold, but Smooth is preferred for a softer effect while Form provides more structure [57][62] Question: Can you elaborate on the sequential growth for Jeuveau in Q3? - The company maintained consistent promotional efforts and engaged consumers through loyalty programs, which contributed to the growth [66] Question: What is the split between U.S. and international sales for Jeuveau? - The company does not provide detailed segment reporting but noted growth in both U.S. and international markets [71][73] Question: What are the potential impacts of tariffs on the business? - Management is closely monitoring tariff developments and has taken steps to mitigate potential impacts, including pulling forward inventory purchases [103][104]